Skip to main content

COVID-19 Vaccine AstraZeneca (ChAdOx1-S) solution for injection multidose vial, AstraZeneca Pty Ltd, CON-770

Product name
COVID-19 Vaccine AstraZeneca (ChAdOx1-S) solution for injection multidose vial
Sponsor name
AstraZeneca Pty Ltd
ARTG
349072
Consent start
Consent no.
CON-770
Standard
Therapeutic Goods Order No. 91 - Standard for labels of prescription and related medicines (TGO 91)
Non-compliance with standard
The product does not conform with the requirements of section 6 (interpretation - name of an activeingredient), paragraphs 8(1)(b), 8(1)(c), 9(3)(a), subparagraph 10(3)(a)(iii), paragraph 10(4)(b), subparagraphs 11(2)(f)(iv), 11(2)(k)(ii) and 11(3)(b)(iii) of Therapeutic Goods Order No. 91 - Standard for labels of prescription and related medicines, in that The name of the active ingredient (ChAdOx1-S [recombinant]) has not been accepted for inclusion on the Australian Approved Names List.The quantity or proportion of active ingredient in the medicine is not shown on the labels.The quantity of the active ingredient is not shown on the label.Quantity of the excipients per dose volume (i.e. per 0.5 mL) not shown on the carton.Primary pack label does not comply with section 8, 9 and subsection 10(3).Expression of quantity or proportion of active ingredients not shown on the labels.A number of biological organisms (i.e. 'vp '“ viral particles') present per metric unit, are not shown on the label.The potency units (i.e. 'vp '“ viral particles') are not expressed on the labels.
Conditions imposed
          This consent applies only to the AU sourced batches, which utilise the 'AU' carton labels (primary pack) and 'AU' vial labels (small container as the capacity is less than 25 mL).       Non-compliance is limited to Therapeutic Goods Order 91 requirements only.       
Therapeutic product type
Prescription medicines

Help us improve the Therapeutic Goods Administration site